

Rosaria Orlandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2650174/publications.pdf>

Version: 2024-02-01

51
papers

2,052
citations

257101

24
h-index

243296

44
g-index

51
all docs

51
docs citations

51
times ranked

3201
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma profile of immune determinants predicts pathological complete response in locally advanced breast cancer patients: a pilot study. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	0
2	Collagen ultrastructural symmetry and its malignant alterations in human breast cancer revealed by polarization-resolved second-harmonic generation microscopy. <i>Journal of Biophotonics</i> , 2020, 13, e202000159.	1.1	24
3	Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. <i>Cells</i> , 2020, 9, 434.	1.8	4
4	Extracellular matrix proteins as diagnostic markers of breast carcinoma. <i>Journal of Cellular Physiology</i> , 2018, 233, 6280-6290.	2.0	49
5	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. <i>Breast</i> , 2018, 39, 46-52.	0.9	11
6	Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 410.	1.8	27
7	Noninvasive strategies for breast cancer early detection. <i>Future Oncology</i> , 2016, 12, 1395-1411.	1.1	13
8	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. <i>Cell Reports</i> , 2016, 17, 233-248.	2.9	84
9	miR-9 and miR-200 Regulate PDGFR β -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 5562-5572.	0.4	74
10	Abstract A18: miR-9 and miR-200 regulate PDGFR β -mediated endothelial differentiation of neoplastic cells in triple-negative breast cancer. , 2016, , .		0
11	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. <i>Journal of Breath Research</i> , 2015, 9, 031001.	1.5	25
12	Molecular portrait of breast cancer in Chinese reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. <i>Cancer Medicine</i> , 2015, 4, 1016-1030.	1.3	31
13	Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. <i>Expert Review of Proteomics</i> , 2015, 12, 695-701.	1.3	23
14	Stromal Responses among Carcinomas Letter. <i>Clinical Cancer Research</i> , 2014, 20, 1396-1396.	3.2	0
15	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. <i>Annals of Oncology</i> , 2014, 25, 352-357.	0.6	53
16	Down-modulation of SEL1L, an Unfolded Protein Response and Endoplasmic Reticulum-associated Degradation Protein, Sensitizes Glioma Stem Cells to the Cytotoxic Effect of Valproic Acid. <i>Journal of Biological Chemistry</i> , 2014, 289, 2826-2838.	1.6	24
17	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	2.1	39
18	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. <i>PLoS ONE</i> , 2013, 8, e56761.	1.1	41

#	ARTICLE	IF	CITATIONS
19	Abstract 4269: Opposite effect of ECM features in breast carcinoma progression according to tumor cell differentiation. , 2012, , .		0
20	Abstract 5642: Wound-healing drainages contribute to triple negative breast cancers aggressiveness. , 2012, , .		0
21	Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 2010, 10, 378.	1.1	55
22	Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cellular Oncology, 2010, 32, 361-72.	1.9	48
23	Functional Characterization of Two Secreted SEL1L Isoforms Capable of Exporting Unassembled Substrate. Journal of Biological Chemistry, 2009, 284, 11405-11415.	1.6	13
24	MALDI-MS/NIST library approach for colorectal cancer diagnosis. Rapid Communications in Mass Spectrometry, 2009, 23, 2839-2845.	0.7	13
25	Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology, 2008, 214, 357-367.	2.1	311
26	Relationship between p53 and p27 expression following HER2 signaling. Breast, 2007, 16, 597-605.	0.9	16
27	SEL1L a multifaceted protein playing a role in tumor progression. Journal of Cellular Physiology, 2006, 208, 23-38.	2.0	36
28	Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction. Proteomics, 2005, 5, 2433-2442.	1.3	27
29	Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. Clinical Chemistry, 2005, 51, 2229-2235.	1.5	166
30	Imatinib mesylate in chordoma. Cancer, 2004, 101, 2086-2097.	2.0	250
31	SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene, 2003, 22, 6359-6368.	2.6	37
32	Production of a monoclonal antibody directed against the recombinant SEL1L protein. International Journal of Biological Markers, 2002, 17, 104-111.	0.7	14
33	SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Cancer Research, 2002, 62, 567-74.	0.4	37
34	Allelic polymorphisms in the transcriptional regulatory region of human SEL1L. Mutation Research - Mutation Research Genomics, 2001, 458, 71-76.	1.2	5
35	Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage 1 Edited by J. Karn. Journal of Molecular Biology, 2001, 313, 965-976.	2.0	50
36	The Gly571arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor. Journal of Cellular Physiology, 2000, 182, 127-133.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β 2 promoter in breast cancer cells. <i>Oncogene</i> , 2000, 19, 1556-1563.	2.6	188
38	Absence of microsatellite instability in breast carcinomas with both p53 and c-erbB-2 alterations. , 1999, 187, 424-427.		4
39	A Linear Region of a Monoclonal Antibody Conformational Epitope Mapped on p185HER2 Oncoprotein. <i>Biological Chemistry</i> , 1997, 378, 1387-92.	1.2	14
40	Binding-induced activation of overexpressed p185HER2 is essential in triggering neuronal differentiation of PC12 cells. <i>Journal of Cellular Biochemistry</i> , 1997, 67, 316-326.	1.2	2
41	New Techniques for the Production of Therapeutic Recombinant Human Monoclonal Antibodies. <i>BioDrugs</i> , 1995, 4, 301-311.	0.7	1
42	Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides. <i>European Journal of Immunology</i> , 1994, 24, 2868-2873.	1.6	20
43	Characterization of a mouse-human chimeric antibody to a cancer-associated antigen. <i>International Journal of Cancer</i> , 1992, 52, 588-593.	2.3	8
44	The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells. <i>FEBS Journal</i> , 1989, 178, 795-802.	0.2	38
45	Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1989, 16, 633-636.	0.3	4
46	Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB. <i>Cancer Immunology, Immunotherapy</i> , 1988, 26, 114-20.	2.0	33
47	The Effect of Human Serum on the Binding Activity of Radiolabelled Monoclonal Antibodies. <i>Tumori</i> , 1987, 73, 547-554.	0.6	0
48	Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. <i>Cancer Immunology, Immunotherapy</i> , 1987, 24, 13-8.	2.0	16
49	Internalization of a monoclonal antibody against human breast cancer by immunoelectron microscopy. <i>British Journal of Cancer</i> , 1987, 55, 357-359.	2.9	17
50	Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups. <i>Hybridoma</i> , 1986, 5, 1-8.	0.9	32
51	Ricin A Chain Conjugated With Monoclonal Antibodies Selectively Killing Human Carcinoma Cells In Vitro. <i>Journal of the National Cancer Institute</i> , 1985, 75, 831-839.	3.0	38